乳腺癌脑转移的药物治疗最新进展★

Drug treatment advances for brain metastases of breast cancer★

摘要:

随着治疗的进步，晚期乳腺癌患者的生存时间得到了明显延长，但患者发生中枢神经系统转移的概率也随之升高。尽管手术和放疗等局部治疗方法仍是脑转移治疗的主要手段，但药物治疗脑转移已经成为近年来研究关注的重点，特别是抗人表皮生长因子受体-2（HER2）药物，如小分子酪氨酸激酶抑制剂等，已经在HER2阳性乳腺癌脑转移的治疗中显示了较好疗效。此外，一些研究也显示，作用于其他靶点的药物，如抗血管生成药物、PARP抑制剂、免疫检查点抑制剂等，对脑转移也有一定疗效。

Abstract:

With the progress of treatment, the survival time of patients with advanced breast cancer has been significantly extended, but the probability of central nervous system metastases in patients is also increased. Although local treatments such as surgery and radiation therapy are still the main means of brain metastases treatment, drug treatment of brain metastases has become the focus of research in recent years. In particular, anti-human epidermal growth factor receptor 2(HER2)drugs, such as small-molecule tyrosine kinase inhibitors, have shown good efficacy in the drug treatment of HER2-positive brain metastatic breast cancer. In addition, some studies have also shown that drugs acting on other targets, such as anti-angiogenic drugs, PARP inhibitors, and immune checkpoint inhibitors, also have a certain effect on brain metastases.